Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 10 clinical trials
featured
A Randomized, Open Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® with DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

A Randomized, Open Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® with DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal

  • 644 views
  • 08 Nov, 2020
  • 5 locations
Study of Doxil in the Treatment of Patients With Refractory Idiopathic Thrombocytopenic Purpura

This study is designed to evaluate the efficacy and safety of single agent Doxil in the treatment of patients with refractory ITP (Idiopathic Thrombocytopenic Purpura).

purpura
splenectomy
platelet count
thrombocytopenia
immunoglobulins
  • 161 views
  • 07 Nov, 2020
  • 1 location
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian Fallopian Tube Or Peritoneal Cancer

Pegylated liposomal doxorubicin (PLD; e.g., Doxil®, Lipodox™) will be administered intravenously on Day 1 and EGEN-001 will be administered intraperitoneally on Day 1, 8, 15, and 22 of a

doxorubicin
peritoneal cancer
doxil
intraperitoneal chemotherapy
  • 226 views
  • 08 Nov, 2020
  • 1 location
TLD-1 a Novel Liposomal Doxorubicin in Patients With Advanced Solid Tumors

TLD-1 is a novel liposomal formulation of doxorubicin (PEG surface) that compared favorably to conventional liposomal formulations of doxorubicin including Caelyx in preclinical in vivo models. Particle features including size, charge distribution, lipid composition and drug release add up to a considerably altered particle behavior compared to Caelyx, potentially explaining …

  • 23 views
  • 28 Jan, 2021
  • 6 locations
A Trial of Doxil and Multiday Vinorelbine in Patients With Metastatic Breast Cancer

This is a phase II trial of Doxil on day 1 and vinorelbine on days 1 and 2 in women with metastatic breast cancer. Administered every 28 days. A study to assess the safety and efficacy

platelet count
measurable disease
vinorelbine
advanced breast cancer
breast cancer
  • 13 views
  • 07 Nov, 2020
  • 2 locations
A Dose Study of Doxil in a Dose Dense 14 Day CDOP/Rituximab Regimen for Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma (NHL)> 60 Years or With Compromised Cardiac Status.

The purpose of this study is to evaluate the feasibility and tolerability of delivering a full dose, on time schedule of dose-dense CDOP-R (cyclophosphamide, doxil, vincristine

b-cell lymphoma
ejection fraction
pegfilgrastim
hodgkin's disease
rituximab
  • 33 views
  • 07 Nov, 2020
  • 1 location
Temozolomide Etoposide Doxil Dexamethasone Ibrutinib and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS)

Background Secondary central nervous system lymphoma (sCNSL) is cancer that has spread to the central nervous system. Most drugs used to treat it do not cross the blood-brain barrier. This makes it hard to treat. Researchers hope that a new combination of drugs may be able to help. Objective To …

b-cell lymphoma
temozolomide
dexamethasone
isavuconazole
anticoagulants
  • 2 views
  • 05 Mar, 2021
  • 1 location
Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide Etoposide Doxil Dexamethasone Ibrutinib Rituximab (TEDDI-R) in Primary CNS Lymphoma

with a novel chemotherapy platform called dose adjusted temozolomide, etoposide, doxil, dexamethasone, ibrutinib, rituximab (TEDDI-R). OBJECTIVE

b-cell lymphoma
temozolomide
dexamethasone
ejection fraction
isavuconazole
  • 1 views
  • 09 Mar, 2021
  • 1 location
Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma

(CC-4047) and liposomal doxorubicin (Doxil) in people with KS. Eligibility People ages 18 and over with KS Design

diastolic blood pressure
systemic chemotherapy
progressive disease
measurable disease
atazanavir
  • 11 views
  • 01 Mar, 2021
  • 1 location
Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer

This phase II trial studies how well pegylated liposomal doxorubicin hydrochloride and carboplatin followed by surgery and paclitaxel work in treating patients with stage II-III breast cancer that does not have estrogen receptors, progesterone receptors, or large amounts of human epidermal growth factor receptor 2 (HER2)/neu protein (triple negative). Drugs …

human epidermal growth factor
metastasis
carboplatin
epidermal growth factor
immunohistochemistry
  • 1 views
  • 25 Jan, 2021
  • 1 location